China - Chengdu Hitachi Pharmaceutical Development Co., Ltd. (stock code: 688222.SH, hereinafter referred to as 'Chengdu Hittor'), a company listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, announced that it has entered into a partnership with Nested Therapeutics, Inc. ('Nested') signed a new drug research and development service contract.

Nested is a biotechnology company developing the next generation of precision cancer therapies. According to the agreement, HitGen will use its DNA-encoded compound library (DEL) technology platform (including the design, synthesis and screening of DEL) to screen for Nested's hit compounds targeting specific targets.

HitGen is a global leader in the development of DEL technology and its application in the field of small molecule new drug development. Its DEL technology platform can design, synthesize and screen physical molecular libraries containing more than 1.2 trillion DNA-encoded compounds. The company's DEL products and high-efficiency screening capabilities have provided new drug discovery services and projects for many institutions and organizations around the world.

Dr. Li Jin, Chairman and CEO of HitGen, said: 'We look forward to working with Nested's research team to provide novel starting compounds for their research projects, to facilitate the development of new drugs, and to help address the unmet needs of cancer patients. HitGen Owning the world's leading DEL technology platform, it is an efficient 'engine' for discovering new drug 'seeds'. As one of the company's four core technology platforms, the DEL technology platform has provided innovative drug discovery projects for many customers and partners Starting compounds. We also look forward to providing valuable results for Nested's research projects.'

About Nested Therapeutics

Nested Therapeutics is a biotechnology company focused on using mutation populations to identify druggable 'pockets' to develop novel small molecule targeted precision cancer therapies. Nested's drug discovery platform uses technologies such as genomics, computational chemistry, proteomics and artificial intelligence to identify untapped mutations that have the potential to improve treatment outcomes for millions of cancer patients.

About Chengdu Leading

Chengdu Hittech Co., Ltd. (Shanghai Stock Exchange stock code: 688222.SH, stock name: Chengdu Hittor) is committed to building a world-class innovative biopharmaceutical company. It is headquartered in Chengdu, China, with offices in Cambridge, UK, and Houston, USA. Subsidiary. The company focuses on the discovery and optimization of new small molecules and nucleic acid drugs, and strives to create an internationally leading platform for DNA-encoded compound library technology (including the design, synthesis, screening and expanded application of DEL libraries), and expands the platform based on molecular fragments and three-dimensional structure information. The core technology platform of drug design technology (FBDD/SBDD), oligonucleotide new drug development related technology (STO) and targeted protein degradation related technology (TPD). HitGen has established cooperation with hundreds of pharmaceutical companies, biotechnology companies, chemical companies, foundations and scientific research institutions around the world through diversified business models such as new drug R&D services, transfer of research projects at different stages, and long-term drug listing. At present, the company has multiple internal new drug projects in different clinical and preclinical stages.

Contact:

Tel: +86-28-8519-7385

(C) 2023 Electronic News Publishing, source ENP Newswire